Drug Shortage Active
FENTANYL CITRATE is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
FENTANYL CITRATE (fentanyl citrate) by Hikma is analgesia. First approved in 1984.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Fentanyl Citrate is a potent synthetic opioid analgesic administered via injection for pain management. It works by binding to opioid receptors in the central nervous system to produce analgesia. The drug has been a foundational pain management agent since its 1984 approval.
Product is in late-stage lifecycle with modest Part D spending; commercial teams face headwinds from approaching loss of exclusivity and generic competition.
analgesia.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain
Working on Fentanyl Citrate offers limited career growth in commercial or clinical dimensions but provides deep expertise in mature-market management, generic competition, and operational excellence. Roles are concentrated in manufacturing, regulatory, and supply-chain functions where this 40-year-old injectable remains a high-volume, mission-critical product.
Worked on FENTANYL CITRATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo